Studies that include HIV remission interventions that target CD8+ T cells should ideally report HLA typing of study participants, clinical information about pre-ART viral loads and duration of infection prior to ART initiation, epitope mapping and evaluation for broadly reactive TCRs, analysis of the long-term durability and functional capacity (including expansion capacity and, ideally, viral inhibition), and lymphoid tissue localization or at least homing potential (e.g., CXCR5 expression) of the CD8+ T-cell response. The gene discussed is CD8A; the disease is infection.